IDEXX RealPCR BVDV RNA Test Introduces Standardization and Flexibility to Real-Time PCR Testing
With an expanded portfolio that includes ELISA and PCR tests, IDEXX now offers BDVD testing solutions to fit every need
WESTBROOK, Maine, August 05, 2014—IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces today the launch of the IDEXX RealPCR BVDV RNA Test, expanding its bovine viral diarrhea virus (BVDV) portfolio and providing standardization at every level of real-time PCR testing. All components of the IDEXX RealPCR Modular System can be ordered separately, totally eliminating the concept of traditional real-time PCR kits.
“With traditional PCR testing methods, it can be a real challenge to monitor and control contamination,” says Christian Leutenegger, worldwide head of PCR, IDEXX. “The IDEXX RealPCR BVDV RNA Test has built-in quality controls and is supported by the IDEXX RealPCR Quality Control System, ensuring complete control at every level.”
The IDEXX RealPCR BVDV RNA Test provides full strain coverage, detecting BVDV types 1 and 2, HoBi-like pestivirus (BVDV type 3) and border disease virus. The test is ideal for use in low-prevalence situations using pooled samples (ear notches, serum/plasma), or to confirm results of other screening tests. Manufactured under the trusted IDEXX Quality Management System, the IDEXX RealPCR BVDV RNA Test offers customers a true advance in real-time polymerase chain reaction (PCR) testing to help combat one of the world’s most costly bovine diseases.
“Each component of the system has been optimized and validated for use together as a complete testing system,” explains Olivier te Boekhorst, vice president and general manager, IDEXX “This BVDV test is the first of the IDEXX RealPCR Modular System that streamlines and simplifies real-time PCR testing.”
For more information about IDEXX BVDV tests, visit idexx.com/bvdv.
About IDEXX Livestock, Poultry and Dairy
Livestock and poultry producers, laboratories, veterinarians and dairy processors depend on IDEXX diagnostic technologies to make confident decisions about animal health, disease management and reproductive efficiency, and to ensure consumers have access to safe, healthy food and milk. Reproducibility, reliability and accuracy are three of the reasons why more than 1 billion IDEXX tests—including dairy residue tests and milk-based diagnostics—have been run worldwide since 1985.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,900 people and offers products to customers in over 175 countries.
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” and similar words and expressions. These forward-looking statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company’s filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at www.sec.gov, at various SEC reference facilities in the United States and via the Company’s website at www.idexx.com).
Contact
Martina Kahila
Commercial Manager, Molecular Diagnostics
IDEXX Livestock, Poultry and Dairy
+41 31 970 62 60
martina-kahila@idexx.com